ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.6 | 8.5 | 1.2 |
| Other income | 0.1 | 5.8 | 0.0 |
| Total income | 0.8 | 14.3 | 1.2 |
| Profit before exceptional items & tax | -0.3 | -0.9 | 0.7 |
| Profit before tax | -0.3 | -0.9 | 0.7 |
| Net profit | -0.2 | -0.7 | 0.7 |
| Operating margin | -37.5% | -6.3% | 58.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -50.00% |
|---|---|
| Operating profit, year on year | -157.10% |
| Operating profit, quarter on quarter | +94.00% |
BSE results filing, NSE: MAYUKH. Figures extracted from the filing.
Sattva Sukun Lifecare Ltd: key numbers
- Share price
- ₹1.15
- Market cap
- ₹44.11 Cr
- Revenue (annual)
- ₹32.25 Cr
- Net profit (annual)
- ₹0.11 Cr
- P/E (TTM)
- -28.5×Sector 46.8×
- Promoter holding
- 3.65%-2.74% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sattva Sukun Lifecare Ltd
All →Sattva Sukun Lifecare Other Announcement
Tavexia Lifecare Ltd board approved changing its RTA from Niche Technologies to Skyline Financial Services. Niche continues until data transition and depository confirmations are complete.
Sattva Sukun Lifecare Q2 FY27 Results: Net Loss of ₹0.4 Cr
Sattva Sukun Lifecare Ltd reported revenue from operations of ₹5 Cr (-70.2% YoY) and a net loss of ₹0.4 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.4 Cr
Sattva Sukun Lifecare Board Meeting Date
Tavexia Lifecare has scheduled a board meeting for November 4, 2026 to consider Q2 results, RTA change, and a fund-raise proposal. All items are proposed only.
Sattva Sukun Lifecare Other Announcement
Tavexia Lifecare Ltd submitted its quarterly shareholding pattern report for the period ended September 30, 2026, in compliance with SEBI regulations.
Sattva Sukun Lifecare Acquisition Worth ₹67.19 Cr
Tavexia Lifecare will acquire a 60% stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore. This strategic investment aims to expand its pharmaceutical sector presence.
- Value
- ₹67.19 Cr
Sattva Sukun Lifecare Annual General Meeting
Tavexia Lifecare Limited concluded its 46th Annual General Meeting on September 30, 2026. Shareholders approved the financial statements, auditor appointment, related party transactions, and director re-appointment.